Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 4 clinical trials
Examination How the Administration Period of Teriparatide Affects Bone Metabolism and Bone Mineral Density Prior to Denosumab Therapy

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in osteoporosis patients: The administration period of teriparatide is less than 6 months and thereafter, denosumab for 24 months. The administration period of teriparatide is from 6 to 12 months and thereafter, …

teriparatide
bone mineral density
osteoporosis
forteo
denosumab therapy
  • 130 views
  • 15 Feb, 2022
  • 1 location
Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in Japanese osteoporosis patients after 2-year-denosumab therapy: SERM and eldecalcitol

osteoporosis
bisphosphonate
denosumab therapy
denosumab
  • 13 views
  • 01 Feb, 2022
  • 1 location
Denosumab Sequential Therapy

for about 6 months. How to prevent bone loss after denosumab therapy is an important issue, especially when considering the compliance, persistence, or other comorbidities of the patient. We want to

  • 0 views
  • 27 Jan, 2021
  • 1 location
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

This randomized open label clinical trial will evaluate the effect of continued denosumab alone over 18 months versus denosumab with added abaloparatide for 18 months. 70 postmenopausal women will be enrolled over a period of 18 months. The co-primary outcomes will be group differences in bone mineral density (BMD) of …

  • 0 views
  • 23 Feb, 2021
  • 1 location